Exegenesis Bio
PrivateLast Round
Series B
Extension
Jun 23, 2021
Total Funding Raised
$70M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Exegenesis Bio is a biotechnology company that develops cell and gene therapies to treat multiple diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Medical AI, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Exegenesis Bio Comparables
Compare Exegenesis Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Capsida Biotherapeutics | 86% | |
| Shanghai Refreshgene Technology Co., Ltd. | 84% | |
| Frontera Therapeutics | 83% |
Exegenesis Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Jun 23, 2021 | ||||
| Series B Extension | Feb 1, 2021 | ||||
| Series B | Aug 3, 2020 |
Exegenesis Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| BioTrack Capital | Series B Extension, Series B |
| Temasek | Series B Extension |
| Lake Bleu Capital | Series B Extension |
| Kaitai Capital | Series B Extension, Series B |
| LYFE Capital | Series B Extension |
| Hillhouse Capital Group | Series B Extension |
| Legend Capital | Series B Extension, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 138% MoM, reaching 4.9K.
Exegenesis Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Exegenesis Bio's valuation, stock price, and market status.
Is Exegenesis Bio a public or private company?
Exegenesis Bio is a private company.
What is the current stock price of Exegenesis Bio?
Exegenesis Bio is a private company with no public stock price. No recent secondary market data is available.
How much is Exegenesis Bio worth (valuation)?
Valuation information for Exegenesis Bio is not publicly available.
Can I buy Exegenesis Bio stock?
Exegenesis Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Exegenesis Bio's last funding round?
Exegenesis Bio's most recent funding round was Series B Extension on June 23, 2021.
Who are the main investors in Exegenesis Bio?
Key investors in Exegenesis Bio include LYFE Capital, Hillhouse Capital Group, Legend Capital.
Will Exegenesis Bio IPO soon?
No public IPO plans have been announced for Exegenesis Bio.
How can I track Exegenesis Bio secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Exegenesis Bio's secondary market activity and sign up for updates.